The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience
More than 20 antiepileptic drugs (AEDs) are currently available for the medical treatment of epilepsies. However, still about 30% of all epilepsies have a drug-resistant course. Even worse, in the case of some epilepsy syndromes, freedom from seizures is almost never achieved. Therefore, new treatme...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2015-05-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/1756285615575696 |
| _version_ | 1818323586937520128 |
|---|---|
| author | Bernhard J. Steinhoff |
| author_facet | Bernhard J. Steinhoff |
| author_sort | Bernhard J. Steinhoff |
| collection | DOAJ |
| description | More than 20 antiepileptic drugs (AEDs) are currently available for the medical treatment of epilepsies. However, still about 30% of all epilepsies have a drug-resistant course. Even worse, in the case of some epilepsy syndromes, freedom from seizures is almost never achieved. Therefore, new treatment options are still necessary, especially if theoretical concepts such as a new mode of action offer new horizons. Perampanel is the first-in-class orally active, selective, noncompetitive antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. The pharmacokinetic profile offers once-daily dosing in the evening as the best route of administration. According to the results of three pivotal placebo-controlled, double-blind phase III trials that investigated perampanel as an adjunctive AED in adult and adolescent patients from age 12 years who had ongoing focal epileptic seizures despite receiving one to three AEDs, perampanel has been widely licensed and introduced. Phase III trials showed superiority of adjunctive perampanel over placebo consistently in the range between 4 and 12 mg. Dizziness and somnolence were by far the leading adverse events. This review covers the clinical trial evidence but also clinical experience with perampanel after launch according to observational studies. |
| first_indexed | 2024-12-13T11:15:03Z |
| format | Article |
| id | doaj.art-6b0ebb02ced74ef588384eae412b8e79 |
| institution | Directory Open Access Journal |
| issn | 1756-2856 1756-2864 |
| language | English |
| last_indexed | 2024-12-13T11:15:03Z |
| publishDate | 2015-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj.art-6b0ebb02ced74ef588384eae412b8e792022-12-21T23:48:38ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28561756-28642015-05-01810.1177/1756285615575696The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experienceBernhard J. SteinhoffMore than 20 antiepileptic drugs (AEDs) are currently available for the medical treatment of epilepsies. However, still about 30% of all epilepsies have a drug-resistant course. Even worse, in the case of some epilepsy syndromes, freedom from seizures is almost never achieved. Therefore, new treatment options are still necessary, especially if theoretical concepts such as a new mode of action offer new horizons. Perampanel is the first-in-class orally active, selective, noncompetitive antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. The pharmacokinetic profile offers once-daily dosing in the evening as the best route of administration. According to the results of three pivotal placebo-controlled, double-blind phase III trials that investigated perampanel as an adjunctive AED in adult and adolescent patients from age 12 years who had ongoing focal epileptic seizures despite receiving one to three AEDs, perampanel has been widely licensed and introduced. Phase III trials showed superiority of adjunctive perampanel over placebo consistently in the range between 4 and 12 mg. Dizziness and somnolence were by far the leading adverse events. This review covers the clinical trial evidence but also clinical experience with perampanel after launch according to observational studies.https://doi.org/10.1177/1756285615575696 |
| spellingShingle | Bernhard J. Steinhoff The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience Therapeutic Advances in Neurological Disorders |
| title | The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience |
| title_full | The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience |
| title_fullStr | The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience |
| title_full_unstemmed | The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience |
| title_short | The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience |
| title_sort | ampa receptor antagonist perampanel in the adjunctive treatment of partial onset seizures clinical trial evidence and experience |
| url | https://doi.org/10.1177/1756285615575696 |
| work_keys_str_mv | AT bernhardjsteinhoff theampareceptorantagonistperampanelintheadjunctivetreatmentofpartialonsetseizuresclinicaltrialevidenceandexperience AT bernhardjsteinhoff ampareceptorantagonistperampanelintheadjunctivetreatmentofpartialonsetseizuresclinicaltrialevidenceandexperience |